Diabetes is a chronic metabolic disease characterized by elevated blood glucose due to insufficient insulin production, ineffective insulin action, or both. Persistent hyperglycaemia can damage blood vessels, nerves, kidneys, eyes, and other organs over time. Type 2 diabetes accounts for the vast majority of diabetes cases.
The CONDOR randomized clinical trial found brolucizumab better preserved visual acuity than panretinal photocoagulation in proliferative diabetic retinopathy at week 54. Brolucizumab also reduced vision-threatening complications and center-involved diabetic macular edema events, while showing more intraocular inflammation.
U.S. insulin glargine and biosimilar developments in 2026 included CivicaScript's low-cost launch and California's CalRx rollout. The global insulin biosimilars market reached US$2.5 billion in 2025 and is projected to reach US$6.0 billion by 2033.
A study of 100 adults with diabetes found broad comfort with AI-based diabetic retinopathy screening, but most participants wanted physician oversight. The findings come as AI tools move further into community diabetes care.
Trump secured agreements with 16 pharmaceutical companies tied to TrumpRx.gov, including most-favoured-nation pricing and direct-to-patient discounts. Several companies disclosed price cuts for obesity, diabetes, insulin and other medicines.
Two studies of older adults with type 2 diabetes linked diabetic retinal disease with higher dementia risk. DME and more severe diabetic retinopathy were associated with higher all-cause and vascular dementia risk, but not consistently with Alzheimer’s disease.
The FDA said one pivotal trial plus confirmatory evidence will become the default standard for approval of most new drugs. The shift could extend beyond rare diseases to common conditions affecting millions.
Vermont insurers and employers are scaling back GLP-1 coverage as costs rise, leaving some patients without access. The drugs remain in high demand as studies point to benefits beyond weight loss.
20/20 BioLabs began trading on Nasdaq under ticker AIDX and disclosed a contingent financing agreement of up to $40 million. It later signed an exclusive U.S. license deal with ROKIT to add CKD prediction to OneTest for Longevity.
A study in Ophthalmology found tirzepatide use was associated with lower 12-month risk of new or progressive diabetic retinopathy versus lifestyle intervention alone. The analysis included about 174,000 matched patients.
Generic semaglutide launched in India as Novo Nordisk’s patent expired, with prices starting below Rs 1,300 a month. Doctors and companies said device quality, cold chains and patient support will also shape sales.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07598656 |
Local Delivery of Lactobacillus Reuteri Probiotic as An Adjunct to Non-surgical Periodontal Therapy in Patients With Stage II, III, and IV Periodontitis and Type 2 Diabetes Mellitus |
COMPLETED | NA |
| NCT07591415 |
Validation of an App in the Elderly Population With Diabetes Mellitus. |
COMPLETED | NA |
| NCT07587437 |
Preoperative Use of a Magnetically Controlled Capsule Endoscopy in Patients Undergoing Bariatric Surgery |
ENROLLING_BY_INVITATION | NA |
| NCT07581106 |
Physical Activity During Pregnancy in Women With Pre-existing Diabetes |
NOT_YET_RECRUITING | |
| NCT07567170 |
Satisfaction of Specific Modes Related to Physical Activity in People Living With Type 1 Diabetes and Using an Hybrid Closed-loop System |
RECRUITING | NA |
| NCT07561541 |
Extended Oral Antibiotic Prophylaxis in Diabetic Fracture Patients |
RECRUITING | PHASE4 |
| NCT07560969 |
Addressing Food Access and Physical Activity to Improve Diabetes Prevention Outcomes Among Underserved African Americans |
NOT_YET_RECRUITING | NA |
| NCT07559292 |
Implementing Artificial Intelligence to Prevent Vision Loss From Diabetes |
ENROLLING_BY_INVITATION | NA |
| NCT07557914 |
Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes - A Multicenter, Prospective, Single-arm Clinical Study |
NOT_YET_RECRUITING | PHASE2 |
| NCT07550491 |
Influence of Residual Bone Height on Marginal Bone Loss Around Implants Following Lateral Sinus Floor Augmentation With Deproteinized Bovine Bone Mineral |
COMPLETED |
